Travere Therapeutics, Inc. (TVTX) stock
TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 6/30751% above fair value
$50.24−0.86 (-1.68%)
Close on Nov 18, 2026Market cap $4.74BP/E –Yield –
Travere Therapeutics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Travere Therapeutics's price to book ratio was 199.9× on Nov 11, 2026, against 43.1× a year earlier. Over the last 5 years it ranged from 1.7× to 254.5×, with a median of 13.4×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 199.9× | +153.4 |
| 2025 | Dec 31, 2025 | 46.5× | −41.9 |
| 2024 | Oct 31, 2024 | 88.3× | +85.9 |
| 2023 | Dec 29, 2023 | 2.4× | −11.0 |
| 2022 | Dec 30, 2022 | 13.4× | +7.2 |
| 2021 | Dec 31, 2021 | 6.2× | +1.5 |
| 2020 | Dec 31, 2020 | 4.6× | +2.1 |
| 2019 | Dec 31, 2019 | 2.5× | −0.4 |
| 2018 | Dec 31, 2018 | 2.9× | +0.2 |
| 2017 | Dec 29, 2017 | 2.7× | +0.4 |
| 2016 | Dec 30, 2016 | 2.3× | −0.1 |
| 2015 | Dec 31, 2015 | 2.4× | −236.3 |
| 2014 | Oct 31, 2014 | 238.7× | – |
See a number that looks wrong?